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Background: Flight simulators have been used to train pilots to experience and recognize spatial disorientation, a
condition in which pilots incorrectly perceive the position, location, and movement of their aircrafts. However,
during or after simulator training, simulator sickness (SS) may develop. Spatial disorientation and SS share common
symptoms and signs and may involve a similar mechanism of dys-synchronization of neural inputs from the
vestibular, visual, and proprioceptive systems. Transcutaneous electrical nerve stimulation (TENS), a maneuver used
for pain control, was found to influence autonomic cardiovascular responses and enhance visuospatial abilities,
postural control, and cognitive function. The purpose of present study was to investigate the protective effects of
TENS on SS.
Methods: Fifteen healthy young men (age: 28.6 ± 0.9 years, height: 172.5 ± 1.4 cm, body weight: 69.3 ± 1.3 kg, body
mass index: 23.4 ± 1.8 kg/m2) participated in this within-subject crossover study. SS was induced by a flight
simulator. TENS treatment involved 30 minutes simultaneous electrical stimulation of the posterior neck and the
right Zusanli acupoint. Each subject completed 4 sessions (control, SS, TENS, and TENS + SS) in a randomized order.
Outcome indicators included SS symptom severity and cognitive function, evaluated with the Simulator Sickness
Questionnaire (SSQ) and d2 test of attention, respectively. Sleepiness was rated using the Visual Analogue Scales for
Sleepiness Symptoms (VAS-SS). Autonomic and stress responses were evaluated by heart rate, heart rate variability
(HRV) and salivary stress biomarkers (salivary alpha-amylase activity and salivary cortisol concentration).
Results: Simulator exposure increased SS symptoms (SSQ and VAS-SS scores) and decreased the task response
speed and concentration. The heart rate, salivary stress biomarker levels, and the sympathetic parameter of HRV
increased with simulator exposure, but parasympathetic parameters decreased (p < 0.05). After TENS treatment,
SS symptom severity significantly decreased and the subjects were more able to concentrate and made fewer
cognitive test errors (p < 0.05).
Conclusions: Sympathetic activity increased and parasympathetic activity decreased after simulator exposure. TENS
was effective in reducing SS symptoms and alleviating cognitive impairment.
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Simulators are used increasingly not only in research and
training, but for consumer entertainment, industry, and
medicinal applications as well. Sophisticated motor vehicle
and flight simulators that provide realistic perception of
movement are used in driving and aviation training. With
strict control of environmental conditions, the use of
simulators allows for workload assessment or procedural
improvement [1]. Simulators have been used for the evalu-
ation or cognitive rehabilitation of patients recovering
from anesthesia and those with post-traumatic stress
disorders or traumatic brain injury [2,3]. There are many
advantages to simulator-based training besides the positive
transfer of training effects. For example, compared to dri-
ving or flying in a real environment, a test in simulator is
safe, economical, and allows for the assessment of partici-
pants in a controlled environment, tailoring situations that
are sensitive to people with specific needs, and testing par-
ticipants under objective and repeatable conditions.
Despite all of the advantages of simulators, the issue of
motion sickness (MS) in simulator use remains topical.
Simulator-induced MS consists of a wide range of symp-
toms and signs experienced during or after a simulator ses-
sion and has been referred to as simulator sickness (SS),
simulator aftereffects, or simulator adaptation syndrome
[4]. The incidence of SS varies widely across simulators
and conditions. For fixed-wing and rotary-wing aircraft
simulators, the incidence rates of SS range from 10 − 47%
and 26 − 69%, respectively [5]. The symptoms and signs of
SS include dizziness, spinning sensation, drowsiness,
confusion, motor dyskinesia, visual flashbacks, pallor, cold
sweating, restlessness, and excessive salivating, and can
progress to nausea and eventually emesis. Less commonly
described accompaniments of simulator exposure include
postural and eye/hand incoordination and sopite syndrome
[6,7]. Like MS, many of the signs of SS have been attri-
buted to increased activation of the sympathetic nervous
system [8]. It is well established that severe MS is associ-
ated with decreased cognitive function and negatively af-
fects psychomotor performance [9,10]. SS may cause stress
for those completing assignments on simulators, interfere
with the measurement accuracy or effectiveness of training
or therapy, lower participant motivation, or even cause
complete abandonment of the task. Some of the learned
behaviors such as reducing head movement in a flight
simulator with the purpose of avoiding SS might not be
appropriate or safe for actual flight. Another possible draw-
back of SS is the potential for dangerous aftereffects. More
than 10% of participants will experience pronounced after-
effects such as ataxia, loss of balance, and flashbacks [4,11].
Spatial orientation may also be affected due to imbalance
or disequilibrium. The disruption of balance and coordi-
nation resulting from exposure to a simulator may be a
safety concern, and such aftereffects could be potentiallyhazardous for simulator users when exiting the simulator
or driving home. Unless remedied in some way, SS will
limit simulator-based training.
Current evidence for controlling or alleviating SS in
simulators is poorly documented. Although there are
some quite effective pharmacological interventions for
MS, most of the proven effective drugs have some side
effects that may affect training efficiency [12]. For ex-
ample, scopolamine, one of the most promising drugs
for MS prevention, may cause sedation, dry mouth, blu-
rring of vision, and lightheadedness [13]. Oral medica-
tions for SS treatment might not be feasible, as drug
absorption was shown to be impaired due to marked
reduction in gastric motility [14]. Another drawback of
oral medications is the anticipation of prophylactic need
because most peak drug plasma levels are not reached
until several hours after administration. To overcome
these problems, alternative medicine remedies that are
currently used to treat MS should be considered for SS
management. Stimulation of Neiguan (P6) acupoint had
been evaluated as non-pharmacologic intervention for
MS. Although some studies failed to demonstrate signifi-
cant positive effects [15-17], however, cyclic manual
pressure or electrical stimulation to the Neiguan (P6)
acupuncture point suppressed MS symptoms of nausea
and vomiting in a rotating optokinetic drum paradigm
[18]. Transcutaneous electrical nerve stimulation (TENS),
a maneuver that alters cardiovascular autonomic responses
[19-21], enhances visuospatial abilities and cognitive func-
tion [20], had recently been shown to alleviate motion sick-
ness symptoms provoked with Coriolis stimulation [21].
However, the effects of TENS on SS had not been evalu-
ated. The aim of the present study was to investigate the
effects of TENS on flight simulator-induced SS.
Methods
Design
A within-subject crossover design was carried out and
the TREND statement was followed [22]. Each subject
was asked to complete 4 sessions (control, SS, TENS,
and TENS + SS) in a randomized order. A list of random
numbers was determined using a computer program
(Research Randomizer). Numbers were placed in sealed
opaque envelopes before the beginning of the study so
that randomization was concealed from the recruiter.
Each session consisted of 4 phases: phase 1 (10 minutes),
consisting of preparation and recording of baseline
physiologic parameters; phase 2 (10 minutes), electrical
stimulation (for TENS and TENS + SS sessions); phase 3
(20 minutes), SS stimulation (for SS and TENS + SS
sessions) and electrical stimulation (only in TENS + SS
sessions); and phase 4 (30 minutes), the post-test period
(Figure 1). To compensate for any learned behaviors and
to prevent the carryover of intervention, sessions were
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Figure 1 Schematic illustration of the experimental protocol.
Empty arrows indicate objective assessments and solid arrows
indicate subjective assessments. Solid line with arrowhead indicate
heart rate recording. Dashed lines with arrowheads indicate
transcutaneous electrical nerve stimulation (TENS) treatment or
simulator exposure sessions. HR, heart rate; SS, simulator sickness;
VAS-SS, Visual Analogue Scales for evaluating Sleepiness Symptoms;
Pre-20 and Pre-10, 20 and 10 minutes before simulator exposure,
respectively; SS15 and SS30, 15 and 30 minutes after simulator
exposure, respectively.
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was performed by a person blinded to session.
Participants
Healthy, non-smoking, young male were recruited from
trainees taking aviation physiology refresh course in
Aviation Physiology Research Laboratory of Gangshan
Armed Forces Hospital during July, 2009 and June, 2010
for this study. All subjects were screened for vestibular,
visual, cardiovascular, respiratory, and gastrointestinal
tract disorders. We calculated sample size using a statis-
tical power analysis program (G*-power) for one tail
with a medium effect size, setting statistical significance
to α = 0.05 and a power of 0.80. Our calculations yielded
an estimate of at least 15 subjects in the group. Each
subject provided written informed consent prior to the
study. All of the study procedures were in accordance
with the declaration of Helsinki and the ethical standards
of the human research advisory committee. Subjects were
instructed to refrain from the use of medications, alco-
holic substances, and caffeinated beverages for 24 hours
before and at the time of each study session. They were
instructed to be well rested before each study session. All
tests were performed between 1:30 PM and 5:00 PM to
comply with the schedule of the simulator and to control
for possible time-of-day effects.
Experimental protocol
All test sessions were performed in the DISO trainer in
the Aviation Physiology Research Laboratory of Gangshan
Armed Forces Hospital. In the Control and TENS
sessions, the participants sat quietly in the DISO trainer
without activating the simulator while physiological record-
ings were made. During phase 3 of the SS and TENS + SS
sessions, SS was induced with the DISO trainer, a motion-
based flight simulator used to simulate a number of
illusions and spatial disorientation conditions that arecommonly encountered in the aviation environment. The
simulator was jointly designed by the Aerospace Physi-
ology Research Laboratory and the Chung-Shan Institute
of Science and Technology. The cabin of the spatial dis-
orientation trainer is configurable for the cockpit of F-5E
and F-16 fighter aircraft and generic helicopters, with a
total of 45 training courses in active and passive mode. It
employs a 200 × 200 km terrain, landform, and surface
feature board database. Visual display of the simulator is
supported with a 3-channel 120° (H) × 30° (V) Collimated
Display System for improved field of depth. This device
incorporates a 6 degree of freedom (pitch, roll, yaw,
heave, surge, and sway) electric pneumatic motion plat-
form (E-Cue 636–4500, Fokker Controls, Netherlands)
with a 360° rotational axis (AMST-System technik
GmbH, Austria) capable of generating adequate linear
and rotatory motion cues to simulate possible flight
environments and disorienting visuovestibular condi-
tions. For the current study, 8 flight profiles were chosen:
take-off illusion, weather condition, false horizon, light
confusion, the leans, autokinesis, semicircular canal defect,
and Coriolis illusion. Each subject may request the simula-
tion session be terminated if they found the SS symptoms
to be unbearable; otherwise, the entire duration of the
simulation (approximately 30 minutes) was completed.
Intervention
For the TENS and TENS + SS sessions, 30 minutes
(complete duration of phases 2 and 3) of TENS was
administered at the midline posterior nuchal region
(1.5 cm lateral to the seventh cervical vertebra spinous
process) and right Zusanli acupoint (located 1 finger
breadth lateral to the tibial anterior crest, about 4 finger
widths below the knee). The electrical stimulation was
conducted in the simulator using a self-contained,
battery-operated, dual channel transcutaneous electrical
nerve stimulator (SW320, SHINMED, Taiwan, ROC) at
a pulse rate of 100Hz. Per the manufacturer’s instruc-
tions, the participants set the level of intensity (1
through 10) at the highest comfortable setting, as the
intensity setting varies individually. In SS session,
placebo-TENS was applied in which the TENS elec-
trodes were in place but no stimulation was given.
Outcome measures
Prior to test session, MS susceptibility of all subjects
was evaluated with the Motion Sickness Susceptibility
Questionnaire (MSSQ), the validated Chinese version of
the original questionnaire [23,24]. The questionnaire
recorded participants’ previous everyday life MS experi-
ences (e.g., different transportation methods and amu-
sement park rides) during childhood (before age 12,
subscale MSSQ-A) and adulthood (after age 12, subscale
MSSQ-B). Frequencies of exposure to potential MS-
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a 5-point scale. Outcome indicators including SS symp-
toms and subjective sleepiness were evaluated with the
Simulator Sickness Questionnaire (SSQ) and Visual
Analogue Scales for evaluating Sleepiness Symptoms
(VAS-SS) before phase 1 and after phase 3 of the expe-
riment, respectively [25]. Cognitive function was evalu-
ated with the d2 test [26].
The SSQ is a well-validated self-report symptom
checklist designed to detect the prevalence and severity
of 16 possible symptoms associated with SS (general dis-
comfort, fatigue, headache, eyestrain, difficulty focusing,
increased salivation, sweating, nausea, difficulty concen-
trating, fullness of head, blurred vision, dizzy with eyes
open, dizzy with eyes closed, vertigo, stomach awareness,
and burping) [27]. The degree of severity was rated using
a 4-point scale ranging from 0 to 3 (not present, slight,
moderate, and severe). The Nausea subscale (general
discomfort, increased salivation, sweating, nausea, diffi-
culty concentrating, stomach awareness, and burping),
Oculomotor subscale (general discomfort, fatigue, head-
ache, eyestrain, difficulty focusing, difficulty concentra-
ting, and blurred vision), and the Disorientation subscale
(difficulty focusing, nausea, fullness of head, vertigo,
dizzy with eyes open, dizzy with eyes closed, and blurred
vision) provide diagnostic information about particular
symptom categories. The overall SS score and the
subscale scores are obtained by first summing the values
for symptoms in the specific subscale then multiplying
by a unique weighting factor. The VAS-SS is used to
assess sleepiness. The test requires each subject to assess
“how did you feel in the last 10 minutes” with respect to
10 sleepiness symptoms: to have tired eyes, to have heavy
eyelids, difficulty to direct one’s eyes, difficulty to maintain
open eyes, yawns, motor difficulties, strong sleepiness, to
feel dizzy, difficulty to direct one’s attention, brief and
involuntary microsleeps. For each symptom, the subjects
responded by making a stroke with a pen on a 100-mm
line with the left end indicating “not at all” and the right
end indicating “very much.” The distance in mm of the
mark measured from the left end of the line was used as a
dependent variable.
The d2 test [26], a standardized paper-and-pencil test,
was utilized to assess cognitive function, more specifically
the visual attention before (during phase 1) and after SS
induction (after phase 3) in each session. The test form
consisted of 14 test lines in a landscape paper layout with
47 characters in each line. Each character consisted of a
letter, “d” or “p,” marked with 1, 2, 3, or 4 small dashes.
The respondent was required to scan the lines and cross
out all occurrences of the letter “d” with 2 dashes while
ignoring all other characters. Two types of errors are
calculated: errors of omission (missing characters that
should have been crossed out) and errors of commission(crossing out characters that should not have been crossed
out). The test results included the following norm-
referenced scores: the total number of items processed
([TN], the sum of all items processed both correctly or
incorrectly), a highly reliable measure of processing speed;
percentage of errors ([E%], the proportion of errors made
across all processed items), a measurement of the qualita-
tive aspects of performance; the total number of items
processed minus errors (TN-E), an indication of the im-
plications of the combined speed and accuracy scores
for attention and inhibitory control; and concentration
performance ([CP], the number of correctly processed
items minus errors of commission), a measure of the
distortion in response style. Prior to commencement of
the study, all subjects were fully trained on the d2 test
to minimize the learning effect.
Other measurements
Salivary stress biomarker level was evaluated. Three mixed
unstimulated saliva samples were collected with Salivette
saliva collecting tubes (Sarstedt, Nümbrecht, Germany) at
each of the following time points: at phase 1 (pre-20) and
15 min (SS15) and 30 min (SS30) after SS induction. The
samples were stored immediately after collection at 0°C
and delivered to the laboratory on the following day,
where samples were frozen at −80°C until analysis. On the
day of the assay, the samples were thawed completely,
supernatants were collected, and sAA activity and cor-
tisol concentrations were measured according to the
manufacturer’s recommendations (Salimetrics Salivary
alpha-amylase Assay Kit and Salimetrics Salivary Corti-
sol immunoassay kit, Salimetrics, USA).
The Polar system (RS 800 wrist unit and WearLink
transmitter, Polar, USA) was used to record the HR of
each participant. HRV was determined by imputing the
HR data into the Nevrokard LT-HRV software (Nevrokard
Kiauta, d.o.o. Slovenia). Power spectrum analysis in the
frequency domain was performed by fast Fourier trans-
formation. The low-frequency power component ([LF],
0.04 − 0.15 Hz), high-frequency power component ([HF],
0.15 − 0.40 Hz), ratio of low-to-high frequency spectra
power (LF/HF), high-frequency ratio (HF/LF +HF), and
low-frequency ratio (LF/LF +HF) were derived.
Data analysis
Data were presented as mean ± standard deviation (SD).
A considerable skewed distribution was observed for
raw HRV and salivary biomarkers data. Therefore, these
values were analyzed after logarithmic transformation as
recommended [28]. Nonparametric statistics were used
to analyze these data. For comparison between sessions, a
repeated-measures analysis of variance (ANOVA) was used.
Correlations between the SSQ and MSSR were assessed by
Spearman rho correlation coefficient calculations. Data
MSSQA












Figure 2 Correlation between childhood (motion sickness
symptom questionnaire [MSSQ]-A) and adulthood (MSSQ-B)
scores of motion sickness susceptibility. ★: high leverage and
high influential point [i.e., the “outlier” (36.34, 38.02)]. Inset:
correlation coefficients between MSSQ-A and MSSQ-B with (n = 15)
and without (n = 14) the outlier.
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Social Sciences (SPSS; version 19.0, SPSS, USA). Results
were considered significant when p < 0.05.
Ethical approval
Ethical approval was given by the Institutional Review
Board in Aviation Medicine Research of Gangshan Armed
Forces Hospital on June 25, 2009.
Results
Participant enrolment
For the current study, 20 participants were recruited and
screened for eligibility and 18 were found to be eligible
and enrolled in the study. All 18 subjects were assigned to
each study condition. 3 subjects were not able to finish all
sessions due to conflict between working and experimental
schedule. A total of 15 participants (age: 28.6 ± 0.9 years,
height: 172.5 ± 1.4 cm, body weight: 69.3 ± 1.3 kg, body
mass index: 23.4 ± 1.8 kg/m2) met the inclusion criteria
and complied with research protocol during the study
period.
Compliance with trial method
Fifteen healthy young men completed 4 test sessions
(control, SS, TENS, TENS + SS) in a randomized order.
The adverse events of the intervention were collected at
points of contact between study staff and participants.
There were no reports of adverse events. All participants
completed post-intervention measurements, and all par-
ticipants' data were included in the intention-to-treat
analysis.
The mean score of childhood MS susceptibility of the
participants (MSSQ-A, 7.49 ± 2.52) was significantly dif-
ferent from (p = 0.032) and correlated with their adult
score (MSSQ-B, 4.85 ± 2.48) (r = 0.902, p = 0.000, Figure 2).
Regardless of severity, 80% of the participants reported at
least 1 SS symptom after simulator exposure. Of all symp-
toms, increased salivation (n = 12) was most frequently
experienced, followed by vertigo (n = 8), fullness of head,
eye strain, and dizzy with eyes closed (n = 7). Five parti-
cipants suffered nausea. The least reported discomforts
were sweating (n = 1), stomach awareness (n = 2), and
headache (n = 2). In terms of the severity of SS, the most
reported symptom severities were “slight,” with only 2
symptoms (eye strain and increased salivation) reported
in the “moderate” range. Regarding the profile of the SSQ
subscales, disorientation symptoms were predominant,
followed by nausea symptoms. The severity of SS as re-
flected by the total SSQ score increased after the simulator
session, which was significantly decreased following TENS
intervention (p < 0.05) (Figure 3). Neither childhood nor
adult motion sickness susceptibility predict the degree of
SS symptom severity (Table 1).An increase of HR was observed after simulator expos-
ure (73.1 ± 4.0 to 78.6 ± 4.2 bpm, p < 0.05, Table 2). HRV
analysis revealed that with the development of SS, there
was an increase in HR fluctuation, which was reflected
in the increase of LF power and a decrease of HF power.
The LF/HF ratio also increased with SS (p < 0.05). All of
these effects of SS on HRV were eliminated with TENS
treatment (Table 2).
Two salivary stress biomarkers, sAA and cortisol, were
evaluated to reflect the acute stress responses of the
adrenomedullary and adrenocortical systems due to SS,
respectively. The sAA activity, but not salivary cortisol
concentration, elevated with simulator challenge. TENS
did not affect salivary biomarker levels (data not shown).
With the development of SS, the subjects’ self-rating
of sleepiness increased and their performance in the d2
test deteriorated, as reflected by elevated VAS-SS scores,
smaller TN, increased E%, and poor CP. After TENS
treatment, their degree of sleepiness was comparable to
baseline levels and the subjects showed increased con-
centration in the cognitive test with fewer errors. Specif-
ically, processing speed and concentration increased
while errors decreased (p < 0.05, Table 3).
Discussion
In simulators, moving visual scenes and vehicular mo-
tion challenge perception, which predisposes individuals
to SS. Some SS symptoms such as fatigue, drowsiness,
difficulty focusing, and difficulty concentrating affect
spatial orientation and cognitive performance [7]. The
finding that performance declined in our subjects suffer-
ing from SS, in accordance with previous studies in MS
































































Figure 3 Simulator sickness symptom rating (SSQ) scores in SS sessions (filled circle) and TENS + SS (empty circle) sessions. Data were
presented as mean ± standard deviation (SD). *p < 0.05.
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pharmacological agents, alternative therapeutic moda-
lities such as acupuncture, acupressure, and electro-
acupuncture had been tested. Conflicting results have
been reported in previous studies in which acupressure
or electroacupuncture were applied for the prevention
or treatment of MS, with success in some trials [30-32],
but not in others [15,16]. The primary finding from this
study demonstrated that TENS was effective in reducing
SS symptoms and negating the impact of SS on cognitive
performance.
The mechanism of TENS is unclear. We simultaneously
stimulated 2 sites in our TENS protocol with presumably
different mechanism of actions. Neck proprioceptiveTable 1 Intercorrelations between motion sickness
susceptibilities and simulator sickness symptom ratings
Simulator sickness questionnaire (SSQ) scores
Nausea Oculomotor Disorientation Total
MSSQ-A 0.059(0.861) 0.120(0.670) 0.240(0.390) 0.242(0.384)
MSSQ-B −0.039(0.890) 0.133(0.636) 0.227(0.417) 0.228(0.415)
MSSQ-A: Motion Sickness Susceptibility score A for children (<12 years); MSSQ-
B: Motion Sickness Susceptibility score B for adults (>12 years). Data are
Spearman rho’s correlation coefficients (p-value in parentheses).inputs play a major role in body segment position and
orientation in space and during locomotion [33]. Electrical
stimulation to the midline posterior nuchal region has
been shown to improve visuospatial function in patients
[34,35]. The preventive effects of TENS might involve
modifying proprioceptive signaling processes by vibratory
stimulation of the neck muscles. Electrical stimulation to
nuchal spinal segment had direct effects on central ner-
vous system. For example, electrical stimulation of C2
increases activation of the dorsal cochlear nucleus through
the somatosensory pathway [36]. Whether other central
mechanisms play a role awaits further study. The Zusanli
acupoint was chosen as the second acustimulation spot, as
acustimulation of this site had been shown to enhance
the regularity of gastric myoelectrical activity [37] and was
reported to be beneficial in reducing chemotherapy-
induced acute vomiting [38]. The arrangement of the
TENS protocol in the present study also involved practical
considerations. Due to the requirement that the subjects
used their hands to fly in the simulator as well as previous
reports of inconsistent effects, the Neiguan (P6) acupunc-
ture point was not used as an electrostimulation site.
Past occurrence and severity of MS has been used to
predict performance and susceptibility of MS, and a
Table 2 Effects of simulator sickness (SS) and transcutaneous electrical nerve stimulation (TENS) on various
physiological parameters
Phase 1 Phase 2 Early post-test Late post-test
(Pre-20 to pre-10 min) (Pre-10 min to 0 min) (30 min to SS15 min) (SS15min to SS30 min)
SS SS + TENS SS SS + TENS SS SS + TENS SS SS + TENS
HR (bpm) 73.09 ± 13.27 76.65 ± 8.95 74.22 ± 14.36 74.22 ± 9.15 77.15 ± 18.10 75.41 ± 9.64* 78.59 ± 13.85# 76.23 ± 7.10*
LF/(LF + HF) 0.52 ± 0.17 0.60 ± 0.06 0.51 ± 0.18 0.57 ± 0.08 0.70 ± 0.11# 0.55 ± 0.11* 0.75 ± 0.06# 0.58 ± 0.10*
HF/(LF + HF) 0.48 ± 0.17 0.40 ± 0.06 0.49 ± 0.18 0.43 ± 0.08 0.30 ± 0.11# 0.45 ± 0.11* 0.25 ± 0.06# 0.42 ± 0.10*
LF/HF 1.43 ± 0.87 1.66 ± 0.44 1.37 ± 0.75 1.51 ± 0.50 3.00 ± 1.46# 1.42 ± 0.57* 3.66 ± 1.74# 1.68 ± 0.78*
SS: simulation sickness; HR: heart rate; LF: low frequency, HF: high frequency; % change compared with pre-20 min presented in parentheses.
*p < 0.05 relative to SS; # < 0.05 relative to baseline (Pre-20 min).
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velopment [39]. In this study, the MSSQ, an instrument
validated for the Chinese population, was adopted to
evaluate SS susceptibility [23]. Consistent with the pub-
lished data, the childhood scores (MSSQ-A) were higher
than and significantly correlated with the adulthood
scores (MSSQ-B), reflecting evolutionary habituation
[23,40]. When the high leverage and high influential point
(labeled by the star sign in Figure 2) is removed from the
analysis, the correlation between MSSQ-A and MSSQ-B
become fair but still significant (n = 14; r = 0.706, p =
0.005) (inset of Figure 2). The existence of the outlier
was possibly due to: (1) the significant inter-individual
variation of motion sickness susceptibility and (2) small
sample size. Childhood MS susceptibility (MSSQ-A score)
was better correlated with SS symptom severity (SSQ
scores; 0.2 < r < 0.6) than adulthood MS susceptibility
(MSSQ-B scores; -0.1 < r < 0.1), although neither of these
correlations reached statistical significance (data not
shown). This finding could be due to small sample size,
but may also reflect model-specific sensitivity to MS
stimulation, as previously reported [40]. The magnitude
of MS susceptibility of our subjects (MSSQ-A, 7.49 ±
2.52; MSSQ-B, 4.85 ± 2.48) was not comparable to
published normative data by Golding (28.8 ± 23.3 and
16.7 ± 17 for the MSSQ-A and MSSQ-B, respectively)
and Klosterhalfen et al. (both MSSQ-A and MSSQ-BTable 3 Effects of TENS on attention and sleepiness
Control SS TENS TENS + SS
TN 254.8 ± 41.7 235.6 ± 37.3* 251.6 ± 38.6 257.1 ± 38.9#
E% 20.8 ± 22.1 29.9 ± 19.3 22.3 ± 20.2 19.3 ± 19.9#
TN-E 210.3 ± 83.6 171.8 ± 74.5* 202.6 ± 77.5 214.6 ± 77.8#
CP 254.7 ± 41.7 235.4 ± 37.2* 250.8 ± 38.8 256.8 ± 38.9#
VAS-SS 3.2 ± 3.8 10.4 ± 10.1* 4.0 ± 6.0 5.1 ± 5.9#
SS, simulator sickness; TENS, transcutaneous electric nerve stimulation.
TN, E%, TN-E, CP are all parameters of the d2 test. TN, Total Number of item
processed; E%, Percentage of Errors; TN-E, Total number of items minus error
scores; CP, Concentration Performance. VAS-SS, Visual Analogue Scales for
evaluating Sleepiness Symptoms.
*p < 0.05 relative to control; #p < 0.05 relative to SS.scores, ~20) [23,24]. Possible explanations for these dif-
ferences include differences in subject numbers, ethnicity,
gender, test modality, and experimental designs. Our sub-
jects were all males, while Golding and Klosterhalfen et al.
included female subjects (M:F, 70:77 and 37:45, respec-
tively). The MSSQ scores of the current study were lower,
which is likely because women are more susceptible to
MS than men and/or that men had the tendency to under-
report their MS experiences [23,24].
The severity of SS in the current study can be evalu-
ated by total SSQ scores. Scores greater than 20 indicate
sufficient discomfort [41]. Another method to quantify
SS severity is by comparing current data with values
from calibration samples where original SSQ was derived
[27]. Total SSQ score of 15 would represent 75th percent-
ile point in a database of more than 1,100 SSQs from
healthy subjects pooled from ten flight simulators. The
total SSQ score (26.4 ± 5.7) in the current study would
correspond to about 88th percentile points in the pooled
samples. The scores of the disorientation subscale (32.5 ±
7.2; >90th percentile) were the highest among all of the
subscales, followed by nausea subscores (19.1 ± 3.7; about
85th percentile) and oculomotor subscores (11.6 ± 2.9;
69th percentile). Disorientation in the simulator is likely
caused by the pseudo-Coriolis stimuli engendered from
side-to-side head movements in the simulator and self-
motion produced by visual cues [42]. Disorientation, loss
of balance, and ataxia are common problems noted by
trainees and subjects after exiting a dynamic simulator.
High disorientation scores are correlated with postural in-
stability, which may be a safety concern for subjects after
exiting the simulator who may need to walk, climb stairs,
drive, or even fly an airplane [43].
A quantitative relationship between subjective SS and
objective physiological measurements of the central and
autonomic nervous systems have been reported [44]. For
example, HR has been reported to change from baseline
levels following simulator exposure [45]. HR can be modi-
fied by parasympathetic fibers and sympathetic fibers. The
effects of sympathetic and parasympathetic activity on HR
can be monitored with the LF/LF +HF and HF/LF +HF
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estimating the overall balance between the sympathetic
and parasympathetic nervous systems. A higher value
indicates increased sympathetic activity or reduced para-
sympathetic activity. Previous reports revealed conflicting
observations about the HR responses to motion sickness.
HR increases [46,47], decreases [48] or not changed with
MS [49]. Possible explanations for the discrepancy include
individual variation and susceptibility [47], physical cha-
racteristics of the stimuli (different MS models; intensity,
frequency and duration of motion) [50]. HR and sympa-
thetic activity (low-frequency ratio) were elevated while para-
sympathetic activity (high-frequency ratio) was suppressed in
current study, with resultant dominance of sympathetic
over parasympathetic activity (increased LF/HF ratio).
These effects of SS were all eliminated with TENS treat-
ment (Table 2).
Simultaneous TENS treatment significantly ameliorated
SS symptoms, as reflected by the decrease in the total SS
scores. TENS treatment per se did not significantly change
HR and HRV parameters (data not shown). One possible
mechanism by which TENS affects SS is by counteracting
certain pathways that are stimulated by simulator expo-
sure. The finding that TENS effectively ameliorated SS
symptoms in parallel with its effect on HRV supports this
hypothesis. Some other studies failed to demonstrate
treatment effects of electrical or acupoint stimulation for
MS symptoms. Possible explanations for such disparity
include placebo effects, stimulation sites, experimental
models, participants characteristics (for example, gender,
ethnicity).
MS is associated with increased excretion of cortisol.
Epinephrine and noradrenaline are also elevated and may
reflect a nonspecific stress response [51]. Basal levels of
salivary stress biomarkers were correlated with MS tole-
rance or susceptibility in previous experimental paradigms
[52,53]. However, in our subjects, basal cortisol concentra-
tions and sAA activity levels were not associated with the
severity of SS symptoms (i.e., SSQ scores), and hence were
not associated with SS tolerance (data not shown). One
possible cause of this discrepancy is gender, as cortisol had
been shown to predict MS tolerance in women but not in
men [54]. Another potential confounder is the model used
to induce MS. A previous study that used basal sAA levels
to predict MS susceptibility was conducted in parabolic
flight, a markedly stronger stimulus than a flight simulator.
The sAA activity increased after the simulator sessions,
although the levels did not reach statistical significance.
Gordon et al. reported that sAA activity was significantly
higher in subjects that were susceptible to seasickness rela-
tive to non-susceptible subjects [55]. Our results could be
explained by low susceptibility (i.e., lower MSSQ scores) of
our subjects, as stated above. Differences in experimental
models and design could also explain these differences.The present study has some limitations that should be
acknowledged. The flight simulator used in current study
is used to train military personnel. The training schedule
of the simulator is very tight. Thus, including a larger
sample size is not feasible. The small sample size and
inclusion of only young male subjects preclude our ability
to generalize our results to average SS sufferers. Physio-
logical mechanisms of SS and responses to different simu-
lators might not be universal. For example, SS induced by
motion-based simulators and Coriolis stimulation are cate-
gorized as type 1 neural mismatch due to visual-vestibular
conflict, but SS associated with fixed-based simulators and
“Cinerama/Imax sickness" are categorized as type 2a neural
mismatch [50]. Closing the eyes stops the perceived mo-
tion and dramatically reduces vection-induced SS in fixed-
based flight simulators but not motion-based simulators
[27]. Therefore, whether TENS treatment can be applied
to SS induced by other simulators such as virtual reality
awaits future study. In the current study, we did not screen
for susceptible subjects in advance, but carried out cross-
over sessions in randomized orders to decrease the impact
of learning or familiarization effects. It is still possible that
the effect of TENS could be cancelled out, despite the
fact that no significant correlation was found between the
MSSQ and SSQ scores. Testing the effect of TENS on
simulator-specific SS-susceptible subjects could possibly
provide an answer to this question. Approximately 10%
of the subjects will experience pronounced aftereffects, in-
cluding illusory sensations of climbing and turning, per-
ceived inversions of the visual field, and disturbed motor
control [11,56]. Although the aftereffects of simulator ex-
posure usually dissipate in 1–2 hours, persistence of these
effects lasting more than 6 hours have been reported [11].
Measurements of physiological parameters (HR, HRV, and
salivary biomarkers) were performed for only 30 minutes
after simulator exposure in current study. The possibility
of the existence of extended SS aftereffects cannot be com-
pletely ruled out. Thus, we cannot make any claims regard-
ing the effects of TENS on aftereffects. Future studies
should strive to monitor SS and the effects of TENS well
after the simulator session. Data were collected after com-
pletion of all 8 spatial disorientation provocation protocols.
Future studies should focus on individual programs to
determine if SS is more prevalent or severe following par-
ticular maneuvers and the effects of TENS on individual
maneuvers.
The results from this study indicate that the incidence
and severity of SS after exposure to a simulator are not
negligible. These ill effects are characterized by symp-
toms related to the autonomic nervous system. Simula-
tors are used in occupational training, evaluation, and
research. They also allow occupational therapists to con-
duct assessments or remedial sessions in a controlled
environment. Researchers and therapists, however, need
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have identified a countermeasure to prevent the ill
effects of SS. The likely mechanism of action of this
alternative therapy for SS involves modification of auto-
nomic activities. Our findings have clinical and research
implications. Future work includes the adjustment of
TENS parameters such as the duration and location of
electrical stimulation to maximize its effects and to test
the efficacy of TENS in other MS/SS models. Controlled
trials comparing TENS with other treatment modalities
should provide further insight into the optimal method
for controlling SS. Such studies will reveal the beneficial
effects of TENS on simulator performance and aid re-
searchers and occupational therapists in implementing
best practices for their clients receiving simulator-based
training or rehabilitation services. Moreover, conducting
such studies will conclusively address the causes of SS;
only then can effective SS mitigation strategies be devel-
oped and tested.
Conclusions
In summary, cognitive function and autonomic nervous
activity were adversely affected by simulator exposure.
Preventive TENS was effective in reducing SS symptoms
and alleviating cognitive impairment. The beneficial effects
of TENS should aid researchers and occupational thera-
pists in implementing best practices for their clients re-
ceiving simulator-based training or rehabilitation services.
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